2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10821
    Myr-Tat-PKCβII 98%
    Myr-Tat-PKCβII is a cell permeable protein kinase C β II peptide inhibitor. Myr-Tat-PKCβII mitigates the generation of reactive oxygen species in rat ex-vivo and porcine in-vivo ischemia-reperfusion injury.
    Myr-Tat-PKCβII
  • HY-P10833
    C-VGB3 98%
    C-VGB3 is a selective vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer.
    C-VGB3
  • HY-P10846
    HYNIC-CTP 98%
    HYNIC-CTP is a conjugate of HYNIC and CTP (cardiac-targeting peptide). HYNIC-CTP can bind with the radionuclide 99mTc through HYNIC acting as a chelator, forming 99mTc-HYNIC-CTP. 99mTc-HYNIC-CTP is specifically taken up by the heart and used for cardiac imaging, thereby facilitating research into heart diseases.
    HYNIC-CTP
  • HY-P10860
    cMCoFx1 2853605-24-8 98%
    cMCoFx1 is a potent and selective FXIIa cyclic peptide inhibitor. cMCoFx1 has high binding affinity (KD: 900 pM) and inhibitory activity (Ki: 370 pM) for FXIIa. cMCoFx1 can effectively inhibit endogenous clotting pathways, and cMCoFx1 is stable in serum and non-cytotoxic.
    cMCoFx1
  • HY-P10948
    CS-VIP 8 98%
    CS-VIP 8 is a selective allosteric WDR5 protein inhibitor (Ki= 0.008 μM). CS-VIP 8 induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 is promising for research of hematological diseases such as leukemia.
    CS-VIP 8
  • HY-P10949
    pep-10L peptide 1159846-95-3 98%
    Pep-10L peptide is a glycoprotein VI (GPVI) antagonist with Ki values of 180, 225, and 179 μM for CPR, GPO-1, and Type 1 collagen, respectively. Pep-10L peptide has anti-thrombotic effects.
    pep-10L peptide
  • HY-P10972
    GIP (22-51) human 957470-49-4
    GIP (22-51) human (Glucose-dependent Insulinotropic Peptide (22-51) human) is a potent proatherosclerotic peptide hormone consisting of 30 amino acids. GIP (22-51) human can activate the NF-κB signaling pathway, promote the expression of MMP-8, and induce the expression of proinflammatory and proatherosclerotic proteins. GIP (22-51) human can also increase the level of intracellular free Ca2+ in THP-1-induced macrophages. GIP (22-51) human can be used in the research of atherosclerosis.
    GIP (22-51) human
  • HY-P11041
    VS-IP1 98%
    VS-IP1 is an interfering peptide that blocks viperin-mediated STAT1 degradation, thereby preventing coxsackievirus B3 (CVB3)-induced acute heart failure (AHF).
    VS-IP1
  • HY-P11048
    Thrombin-cleavable peptide 2412575-90-5
    Thrombin-cleavable peptide is a type of peptide that can be recognized and cleaved by thrombin. After cleavage, Thrombin-cleavable peptide releases thrombolytic peptides to initiate thrombolysis. Thrombin-cleavable peptide can be used in the research of diseases such as ischemic stroke.
    Thrombin-cleavable peptide
  • HY-P11071
    PCSK9 Inhibitor, EGF-A 98%
    PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis.
    PCSK9 Inhibitor, EGF-A
  • HY-P1112A
    Sarafotoxin S6a TFA 98%
    Sarafotoxin S6a TFA , a sarafotoxin analogue, is a endothelin receptor agonist and has an ETA/ETB selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a TFA elicits the pig coronary artery with an EC50 value of 7.5 nM.
    Sarafotoxin S6a TFA
  • HY-P11143
    IL4RPep-1 1900734-29-3
    IL4RPep-1 is a peptide that can specifically target atherosclerotic plaque, and its target is IL-4 receptor. IL4RPep-1 exhibits good plaque targeting and is not enriched in normal tissues. IL4RPep-1 has potential application as a targeting delivery system or molecular imaging probe for atherosclerosis research.
    IL4RPep-1
  • HY-P11172
    CRGDS 726187-79-7 98%
    CRGDS is a cell adhesion peptide. CRGDS can be used in vascular research.
    CRGDS
  • HY-P11206
    Murine cardiac troponin I peptide 98%
    Murine cardiac troponin I peptide (Murine cardiac TnI peptide) is a murine cardiac troponin I (cTnI) peptide. Murine cardiac troponin I peptide can induce significant myocardial inflammation followed by fibrosis and heart failure with increased mortality in mice model. Murine cardiac troponin I peptide can be used for heart failure research.
    Murine cardiac troponin I peptide
  • HY-P11209
    Knob A peptide GPRPFPAC 1261229-38-2
    Knob A peptide GPRPFPAC is a fibrin knob peptide. PEGylated Knob A peptide GPRPFPAC has enhanced anticoagulant activity.
    Knob A peptide GPRPFPAC
  • HY-P11221
    CLIKKPF 2670995-49-8
    CLIKKPF is a specific peptide segment. CLIKKPF can bind with phosphatidylserine (PS) in the inner layer of the cell membrane with high affinity. CLIKKPF can enhance the targeting ability of nanoparticles. CLIKKPF can be used for research on cardiovascular conditions.
    CLIKKPF
  • HY-P11258
    UPG-108 3090686-88-4
    UPG-108, a peptide compound, is a non-competitive allosteric modulator of Urotensin II receptors (UTR). UPG-108 significantly enhances the efficacy of UTR agonists but reduces the potency of UTR agonists. UPG-111 efficiently induces calcium release and does not cause contraction of rat aortic rings without endothelial denudation. UPG-111 can be used to study various diseases related to the angiotensinergic system.
    UPG-108
  • HY-P11259
    UPG-111 3090687-02-5
    UPG-111 is a peptide compound that acts as a negative allosteric modulator of the Urotensin II receptor (UTR). UPG-111 exhibits a dual inhibitory effect on the vasoconstriction induced by UTR agonists - it reduces both the maximum response intensity and the sensitivity of the agonist. UPG-111 does not induce calcium release or cause contraction of the endothelium-deprived rat aortic rings. UPG-111 can be used for the study of various diseases related to the angiotensinergic system.
    UPG-111
  • HY-P11289
    Intermedin1-53 (Human) 98%
    Intermedin1-53 (Human) is a 53-aa human calcitonin family peptide that reduces the vulnerability of atherosclerotic plaques by inhibiting CHOP-mediated macrophage apoptosis and inflammasome.
    Intermedin1-53 (Human)
  • HY-P11292
    Caloxin 1b3
    Caloxin 1b3, a peptide, is a selective plasma membrane Ca2+ pump 1 (PMCA1) inhibitor. Caloxin 1b3 significantly inhibits PMCA1 Ca2+–Mg2+-ATPase in the rabbit duodenal mucosa than the PMCA4 in the human erythrocyte ghosts. Caloxin 1b3 also increases cytosolic Ca2+ concentration in endothelial cells. Caloxin 1b3 can be used for cardiovascular disorders research.
    Caloxin 1b3
Cat. No. Product Name / Synonyms Application Reactivity